BioSpace News Archive

Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today the publication of a paper in the online edition of the peer-reviewed journal, Nature Communications, entitled: Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade (D’Alise et al, reference below)

New Moms’ Healthy Returns offers employers a single-source, comprehensive and customizable solution for working moms

The U.S. House of Representatives just voted to repeal the prohibition on the use of federal funds to create a “unique patient identifier,” which former Representative Ron Paul, M.D., sponsored in 1998.

Project offers workplace smoking cessation support in five cities in Alberta and Ontario

According to Technavio Research Report “Medical Devices Market by product (therapeutic and surgical devices, patient monitoring, diagnostics and medical imaging devices) and geographical regions (APAC, EMEA, and the Americas) is witnessed to grow USD 119.98 billion, at a CAGR of 5% during the forecast period.

Corporate Insight announced the expansion of its healthcare research product suite with the launch of Health System Monitor as well as Health Plan Mobile Audit.

The world’s biggest survey into public attitudes to health and science publishes today, revealing high overall global trust in doctors, nurses and scientists, and high confidence in vaccines.

After investing more than 100 million U.S. dollars, Sartorius, a leading international partner of biopharmaceutical research and the industry, started up its expanded manufacturing operations in Yauco, Puerto Rico.

An international, randomized Phase 3 study of omidubicel in patients with hematologic malignancies is currently ongoing, and omidubicel has not yet been approved for marketing in the United States or any other jurisdiction.

CT053 has also received IND clearance from the National Medical Products Administration in China four months ago and is the subject of an ongoing phase I clinical trial.